

PHARMACEUTICAL 2018

## IMMUNE DESIGN CORP. Rank 43 of 342







RealRate

PHARMACEUTICAL 2018

## IMMUNE DESIGN CORP. Rank 43 of 342

The relative strengths and weaknesses of IMMUNE DESIGN CORP. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUNE DESIGN CORP. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 108% points. The greatest weakness of IMMUNE DESIGN CORP. is the variable Research and Development, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 177% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	153,143
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,520
Liabilities, Non-Current	0
Other Assets	200
Other Compr. Net Income	925
Other Expenses	84
Other Liabilities	0
Other Net Income	0
Other Revenues	7,195
Property and Equipment	491
Research and Development	43,670
Selling, General and Administrative Expense	16,253

Output Variable	Value in 1000 USD
Assets	153,834
Liabilities	14,520
Expenses	60,007
Revenues	7,195
Stockholders Equity	139,314
Net Income	-52,812
Comprehensive Net Income	-52,350
Economic Capital Ratio	222%

